



9 September 2026

Medicine Supply Alert Notice

Ramipril 1.25mg, 2.5mg, 5mg and 10mg capsules

Priority: Level 2*

Valid until: end of October 2026

Issue

1. Ramipril 1.25mg, 2.5mg, 5mg and 10mg capsules are in limited supply until the end of October 2026.
2. **Note:** a Medicine Supply Alert Notice (MSAN) and a UK-wide Serious Shortage Protocol (SSP) were issued in April 2026 in relation to the shortage of ramipril 1.25mg capsules and the advice and actions contained in both documents remains in effect. Please refer to [MSAN\(2026\)15](#) and [PCA\(P\)\(2026\)07](#) for more details. Please also note that the most up-to-date information on this shortage and other medicine supply issues, including changes to resupply dates and updates to entries, can be accessed via the [Medicine Supply Tool](#), hosted on the Specialist Pharmacy Service (SPS) website (registration required).
3. Ramipril 1.25mg, 2.5mg, 5mg and 10mg tablets remain available but cannot support uplift in demand.
4. Alternative ACE inhibitors and ARBs remain available; however, routine switching is **not** recommended as usage is significantly lower than that of ramipril, so could risk compromising other supply chains.

Advice and Actions

5. Community pharmacy teams and dispensing doctors should:
 - ask patients if they have stock available within their homes and delay dispensing if the patient has one month or more worth of supply;
 - consider purchasing and dispensing short-dated 5mg stock that is available from wholesalers, ensuring that the patient is notified of the expiry date of the stock;
 - conservatively order stock of ramipril capsules in line with usual demand and consider limiting supply to one month to ensure equitable distribution of available stock.
6. Prescribers should:
 - not issue prescriptions for more than one month's supply until the supply issue has resolved;
 - limit switching to another ACE inhibitor or an ARB to cases where this is clinically necessary, taking into account the indication for use, treatment history, comorbidities, intolerance to excipients, as well as local guidance/formularies, and ensure the patient is counselled on the dose regimen (see Additional Information section)

- monitor patients who have switched treatment to ensure blood pressure and/or symptoms remain controlled, and the new agent is tolerated, titrating dose as needed, advising them to seek medical advice if they experience dizziness/light-headedness or other adverse effects after switching. Other blood-pressure and cardiovascular medicines should be optimised, if clinically appropriate.

Additional Information

Clinical Information

7. Ramipril capsules are licensed for the treatment of hypertension, renal disease, and symptomatic heart failure, and for cardiovascular prevention, including after an acute myocardial infarction.
8. Refer to CKS table of [ACE inhibitors](#) and [ARBs](#) in hypertension and [ACE inhibitors in heart failure](#) and [ARBs in heart failure](#) for dosing guidance. Summaries of Product Characteristics (SmPCs) should be consulted for full information on licensed indications and dosing regimens.

Links to further information

- [BNF – Ramipril](#)
- [SmPC – Ramipril](#)
- [NICE CKS – Hypertension: ACE inhibitors](#)
- [NICE CKS - Hypertension: ARBs](#)
- [NICE CKS - Heart failure - chronic: ACE inhibitors](#)
- [NICE CKS - Heart failure - chronic: ARBs](#)

Specialist Pharmacy Service (SPS) website

9. The UK Department of Health and Social Care (DHSC) in conjunction with the Specialist Pharmacy Service (SPS) have launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. To access the online Medicines Supply Tool you need to register with the [SPS website](#). Registration for access to the website is available to UK healthcare professionals and organisations providing NHS healthcare. The tool is located under the Tools tab and then click on the Medicines Supply option.
10. Prescribers, pharmacy professionals, and pharmacy procurement leads in Scotland are encouraged to register with the SPS website and use its Medicine Supply Tool to stay up to date concerning medicines supply disruptions. Please be aware that while medicines supply issues will appear on the SPS website, some of the recommended actions may not always be appropriate / relevant within the Scottish context.

Enquiries

11. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to PharmacyTeam@gov.scot (primary care) or NSS.NHSSMedicineShortages@nhs.scot (secondary care).